Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE-AS: Intravenous Tirofiban After Bridging Therapy for Acute Stroke
NCT07335107Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirofiban in ischemic stroke (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Proportion of modified Rankin Scale score 0 to 2 at 90 days and Symptomatic intracerebral hemorrhage at 48 hours. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07335107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335107.